Acerta Pharma B.V. (A Member Of The Astrazeneca Group)

Acerta Pharma is a European R&D centre of the AstraZeneca group dedicated to the discovery and development of novel innovative drugs for the treatment of haematological malignancies. The company began operations in 2013 with the vision of combining cutting edge science, unique covalent technology, and an experienced, dedicated team in order to deliver novel targeted therapies for patients with cancer. In 2016 AstraZeneca took a majority stake in the company and Acerta Pharma was fully acquired by AstraZeneca in 2021. As part of the significant expansion of our research activities in the Netherlands, we are in the process of building a new research centre in Pivot Park with state-of-the-art research laboratories for more than 140 researchers in Oss, the Netherlands. We are working to develop new treatment options for patients with specific types of blood cancer. Together with our R&D colleagues of AstraZeneca in Gaithersburg, San Francisco, Boston (US), Gothenburg (SE) and Cambridge (UK) we are committed to innovative drug discovery and development, especially in the field of haematological oncology.